LITTLE KNOWN FACTS ABOUT AML WALLET RISK CHECK.

Despite acquiring an entire response with ideal induction therapy, minimum residual disease typically persists, necessitating consolidation therapy to mitigate the risk of relapse by eradicating residual ailment. In patients which have gained 7+3 induction therapy, consolidation therapy is initiated with substantial-dose cytarabine, often known as